The entire source code for Anthropic’s Claude Code command line interface application (not the models themselves) has been leaked and disseminated, apparently due ...

Pfizer is working to get approval on a new vaccine that could protect people against Lyme disease, but the company could see pushback from the government following studies done on the vaccine. "What ...

Pfizer said it is working closely with its biotech partners to “ensure continuity and the successful transition of work.” (iStock/Getty Images Plus) As pharmas like Eli Lilly and Roche bolster their ...

Our comprehensive evaluation suggests that divesting from Pfizer stock (NYSE: PFE) may be the most prudent course of action. Our analysis points a bearish outlook on the stock, with a plausible price ...

That's the good news. The bad news is that while Pfizer "beat" on both sales and adjusted earnings, its earnings as calculated according to generally accepted accounting principles (GAAP) showed a ...

Sanofi SA (NASDAQ: SNY) has been found to have violated the U.K.'s pharmaceutical marketing code after a senior executive made misleading claims in an October 2024 interview, prompting a complaint ...

Pfizer again heads up a physician ranking of vaccine manufacturers, beating Merck & Co. and Moderna to complete an unchanged top three from the last edition of the survey. But, while the rankings held ...

Claude Code generates computer code when people type prompts, so those with no coding experience can create their own programs and apps. By Natallie Rocha Reporting from San Francisco Claude Code, an ...

Pfizer remains a Strong Buy, with oncology breakthroughs, a revitalized obesity pipeline, and aggressive cost savings supporting a compelling value thesis. BRAFTOVI's Phase 3 success and PADCEV + ...

Pfizer Inc. enters 2026 facing earnings pressure from COVID revenue collapse and acquisition-related dilution, despite an aggressive strategic repositioning. The $10 billion Metsera acquisition ...

Deal marks Pfizer's re-entry into obesity treatment market Pfizer shares rise 1.4%, Novo Nordisk falls 1.3% Metsera candidate MET-097i advances to late-stage trials The greenlight from Metsera's ...

Pfizer expects the acquisition to be a drag on earnings through 2030 as it prepares invest in developing Metsera’s drug candidates. (Getty Images) Signed, sealed and delivered, Metsera is finally ...